Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Company

WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing

Fineline Cube Jul 5, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Company Drug

JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma

Fineline Cube Jul 5, 2022

China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...

Company Deals

GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin

Fineline Cube Jul 4, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...

Company Deals

Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development

Fineline Cube Jul 4, 2022

China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...

Company Deals Drug

Brii Biosciences Exercises Option for VIR-3434 in Greater China

Fineline Cube Jul 4, 2022

China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...

Company Drug

Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis

Fineline Cube Jul 4, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...

Company Deals

VivaVision Biotech and Dragon Sail Pharmaceutical Partner on Ophthalmology R & D

Fineline Cube Jul 4, 2022

China’s VivaVision Biotech Inc. has entered into a partnership with compatriot firm Dragon Sail Pharmaceutical....

Company Drug

Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study

Fineline Cube Jul 4, 2022

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...

Company Drug

InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production

Fineline Cube Jul 4, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...

Company Drug

Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention

Fineline Cube Jul 4, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...

Company

Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park

Fineline Cube Jul 4, 2022

Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Fineline Cube Jul 4, 2022

The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...

Company Deals

HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs

Fineline Cube Jul 4, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Policy / Regulatory

NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities

Fineline Cube Jul 1, 2022

The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...

Posts pagination

1 … 588 589 590 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.